US20140322184A1 - Inducible expression cassette, and uses thereof - Google Patents

Inducible expression cassette, and uses thereof Download PDF

Info

Publication number
US20140322184A1
US20140322184A1 US14/357,160 US201214357160A US2014322184A1 US 20140322184 A1 US20140322184 A1 US 20140322184A1 US 201214357160 A US201214357160 A US 201214357160A US 2014322184 A1 US2014322184 A1 US 2014322184A1
Authority
US
United States
Prior art keywords
expression cassette
vector
gene
inducible promoter
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/357,160
Other languages
English (en)
Inventor
Pierre Farfournoux
Alain Bruhat
Celine Jousse
Anne-Catherine Maurin
Julien Averous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Recherche Agronomique INRA
Original Assignee
Institut National De La Recherche Agronomique (Inra)
Centre National De La Recerche Scientifique (Cnrs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Recherche Agronomique (Inra), Centre National De La Recerche Scientifique (Cnrs) filed Critical Institut National De La Recherche Agronomique (Inra)
Publication of US20140322184A1 publication Critical patent/US20140322184A1/en
Assigned to CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) reassignment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FAFOURNOUX, PIERRE, JOUSSE, CELINE
Assigned to INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) reassignment INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AVEROUS, Julien, BRUHAT, Alain, MAURIN, Anne-Catherine
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator

Definitions

  • the present invention relates to an inducible expression cassette including a CARE (C/EBP-ATF Responsive Element) regulatory sequence and the use thereof in the context of gene therapy.
  • CARE C/EBP-ATF Responsive Element
  • Gene therapy is a therapeutic strategy based on the transfer of a gene or genes into a cell or a host organism. It was first hypothesized in the late 1960s, and the first clinical trial took place in the U.S. twenty years later. Its concept, first considered in the context of genetic diseases, was quickly expanded to the treatment of a large number of other pathologies, such as cancers, infectious diseases, or cardiovascular diseases.
  • the goal is to deliver gene medicines to the patient, with most considered strategies using vectors in order to convey the therapeutic gene toward its target cell.
  • the first vectors developed were based on a constitutive expression of the gene medicine. In targeted and nontoxic therapy, it soon appeared preferable to limit the expression of the therapeutic gene to given cell types, at a given time, and/or for a given duration. This led to the use of inducible systems. While many inducible systems are now available to a person skilled in the art, the need for novel systems that are more specific, easily controllable and able to be activated, with a low basal expression, along with minimal side effects, remains an obvious one.
  • the invention relates to an expression cassette including a gene of interest that is operationally linked to an inducible promoter, wherein said inducible promoter includes (i) at least one CARE (C/EBP-ATF Responsive Element) regulatory sequence and (ii) a minimal promoter, as well as the use thereof in treating diseases using gene therapy.
  • said inducible promoter includes (i) at least one CARE (C/EBP-ATF Responsive Element) regulatory sequence and (ii) a minimal promoter, as well as the use thereof in treating diseases using gene therapy.
  • the invention additionally relates to a vector including an expression cassette of the invention, a host cell including a cassette, or a vector of the invention.
  • the invention relates to a pharmaceutical composition including an expression cassette, an expression vector, or a host cell of the invention.
  • the invention furthermore extends to a method for treating diseases using gene therapy, wherein said method includes:
  • said induction is implemented by placing said patient on an amino-acid-deficient diet, preferably involving an essential amino acid.
  • FIG. 1 shows, in diagram form, the eIF2 ⁇ /ATF4 signaling pathway, and in particular the GCN2/ATF4 pathway.
  • FIG. 1A shows the general signaling pathway.
  • FIG. 1B shows, more specifically, the GCN2/ATF4 signaling pathway.
  • the deficiency of any essential (or indispensable) amino acid activates GCN2 kinase.
  • the ATF4 transcription factor is induced. It will bind to the AARE elements located inside the target gene promoter and activate transcription.
  • FIG. 2A illustrates a diagram of the 2XAARE-TK-Luc construction (used in the experimental section) inserted into a retroviral expression vector.
  • FIG. 2B shows the sequence of the 2XAARE-TK-LUC transgene used in the experimental section.
  • FIG. 3 shows the luciferase activity assay in the tissues of transgenic mice carrying a transgene including a vector of the invention with luciferase as the gene of interest, two copies of the CARE sequence from the TRIB3 gene (AARE sequences), and the thymidine kinase minimal promoter (AARE-LUC mice).
  • the CARE-LUC mice were fasted for 16 hrs.
  • the mice were fed for four hours, either with the control diet (CTL) or with a leucine-deficient ( ⁇ leu) diet. After the mice were killed, luciferase activity was assayed in the liver, intestine, pancreas, and brain.
  • CTL control diet
  • ⁇ leu leucine-deficient mice
  • FIG. 4 shows the measurement of luciferase activity after lentivirus was injected into the brain.
  • the lentiviral vectors are injected into the hippocampus of the left hemisphere of rats. Two weeks after the injection, the animals are fasted overnight, then fed with a control diet or with a threonine-deficient ( ⁇ Thr) diet. Six hours after the start of feeding, the animals are killed, and the brains are sampled and dissected. Luciferase activity is measured in the right and left hippocampi and in the remainder of the left hemisphere. Luc activity is then normalized relative to protein content. Two constructions were used: the 2XAARE-TK-LUC construction (described in FIG. 2 ) and the control TK-LUC construction from which the AARE sequences had been removed.
  • FIG. 5 shows the reversibility of the induction of the AARE-LUC transgene in mice following consumption of a leucine-deficient diet.
  • A Visualization of luciferase activity by bioluminescence imaging (detection limit 300-3000) in a mouse fed successively with (1) a control diet (CTL), (2) a leucine-deficient ( ⁇ Leu) diet for four hours, and (3) a CTL diet for 16 hours.
  • CTL control diet
  • B Quantification of bioluminescence in the boxed areas.
  • the luciferase used has a long half-life, which explains the 16 hours needed to significantly reduce luciferase activity.
  • the goal of the present invention is an expression cassette including a gene of interest under the control of an inducible promoter, wherein said inducible promoter includes (i) at least one CARE (C/EBP-ATF Responsive Element) regulatory sequence and (ii) a minimal promoter.
  • said inducible promoter includes (i) at least one CARE (C/EBP-ATF Responsive Element) regulatory sequence and (ii) a minimal promoter.
  • expression cassette refers to an element including specific nucleic acid sequences to be integrated into another nucleic acid molecule or a genome.
  • An expression cassette generally includes one or several genes as well as elements for controlling the expression of said gene(s) (promoter, terminator, etc.).
  • promoter is well known to a person skilled in the art, and refers to a DNA region located near a gene to which RNA polymerase binds in order to start transcription.
  • the promoter is operationally linked to the gene of interest.
  • the expression “operationally linked” means that the promoter sequence is positioned relative to the coding sequence of the gene of interest such that transcription is able to start. This means that the promoter is positioned upstream of the coding region, at a distance enabling the latter's expression.
  • promoters such as constitutive promoters or inducible promoters.
  • inducible promoters are promoters whose activity is controlled by specific environmental conditions or by the presence of a specific compound; they therefore make it possible to control the expression of the gene of interest.
  • the promoters used in the context of the invention may be derived from native genes or from compounds of various elements derived from various natural promoters, or they may include synthetic DNA segments.
  • a “minimal promoter” is defined for the purposes of this document as a promoter consisting of a transcription start site and functional sequences for binding the transcription start complex (TATA-box) inside a cell or a host organism.
  • the promoter used according to the invention is the thymidine kinase minimal promoter or a derivative thereof.
  • the thymidine kinase minimal promoter corresponds to the ⁇ 40 to +50 section of the thymidine kinase sequence, with +1 being the transcription start site (Majumder S, DePamphilis M L, Mol Cell Biol, 1994); it is defined by the SEQ ID NO: 1 sequence.
  • Thymidine kinase minimal promoter sequence (SEQ ID NO: 1) GTCCACTTCGCATATTAAGGTGACGCGTGTGGCCTC GAACACCGAGCGACCCTGCAGCGACCCGCTTAACAG CGTCAACAGCGTGCCGC
  • the term “derived from” corresponds to a nucleic acid sequence that has at least 90% identity with a reference sequence, specifically, at least 95% identity and preferably at least 99% identity.
  • the term “percentage of identity between two nucleic acid sequences” refers to the percentage of identical nucleotides between two compared sequences, said percentage being obtained by the best alignment of the entire sequence.
  • the term “best alignment” corresponds to the alignment that yields the highest percentage of identity. It may be obtained by using various algorithms known to a person skilled in the art (GAP, BESTFIT, BLAST P, BLAST N, FASTA, TFASTA, Genetics Computer Group, 575 Science Dr., Madison, Wis. USA).
  • the promoter may be a eukaryote promoter that must be functional in the host organism.
  • a “CARE (C/EBP-ATF Responsive Element) regulatory sequence” is defined as any target sequence of the eIF2 ⁇ /ATF4 signaling pathway that is capable of binding the ATF4 transcription factor.
  • the ATF4 transcription factor activating transcription factor 4, also referred to as CREB2, TAXREB6, TXREB
  • CREB2 CREB2
  • TAXREB6, TXREB binds to these CARE sequences in order to induce or regulate the transcription of target genes in response to a given environmental stress
  • CHOP C/EBP homologous protein, also called GADD153
  • ASNS Asparagine Synthetase
  • SNAT2 System A Amino Acid Transporter
  • AARE amino Acid Response Elements
  • CARE regulatory sequences that are targeted by the ATF4 transcription factor in case of amino acid deficiency: these AARE sequences are specific CARE sequences targeted in case of phosphorylation of eIF2 ⁇ by GCN2 kinase, with this phosphorylation being induced by an amino acid deficiency, preferably an essential amino acid deficiency.
  • AARE sequences of the invention include, but are not limited to, the CARE sequences of the CHOP, ASNS, SNAT2, ATF3, and TRIB3 genes.
  • the CARE regulatory sequence that is present in the expression cassette includes or consists of a sequence selected from the group including: the CARE sequence of the TRIB3 gene (SEQ ID NO: 2), the CARE sequence of the CHOP gene (SEQ ID NO: 3), the CARE sequence of the ASNS gene (SEQ ID NO: 4), the CARE sequence of the ATF3 gene (SEQ ID NO: 5), and the CARE sequence of the SNAT2 gene (SEQ ID NO: 6), or a derivative thereof.
  • said CARE regulatory sequence that is present in the expression cassette includes or consists of several copies of the SEQ ID NO: 2 sequence, or a derivative thereof.
  • the inducible promoter included in the expression cassette of the invention includes one or more copies of a CARE regulatory sequence. More specifically, said promoter includes at least one, at least two, or at least three copies of a CARE regulatory sequence.
  • the inducible promoter included in the expression cassette of the invention includes two copies of a CARE sequence.
  • the inducible promoter included in the expression cassette of the invention includes two copies of the TRIB3 CARE sequence (SEQ ID NO: 2).
  • the promoter of the expression cassette of the invention includes two copies of the CARE sequence of the TRIB3 gene (SEQ ID NO: 2) and the thymidine kinase promoter (SEQ ID NO: 1).
  • the promoter of the expression cassette of the invention includes or consists of the SEQ ID NO: 7 sequence or a derivative thereof.
  • the CARE regulatory sequence included in the expression cassette is positioned upstream (in position 5′) or downstream (in position 3′) of the minimal promoter. Preferably, it is positioned upstream.
  • the inducible promoter of the invention including at least one CARE (C/EBP-ATF Responsive Element) regulatory sequence and a minimal promoter, is preferably inducible by an amino acid deficiency (of one or more amino acids), more preferably by an essential amino acid deficiency.
  • the gene of interest used in the present invention may derive from a eukaryote organism, a prokaryote, a parasite, or a virus. It may be isolated using any traditional technique in the art, e.g., cloning, PCR, or chemical synthesis. It may be genomic, complementary DNA (cDNA), or mixed-type (minigene).
  • RNA messenger RNA
  • the gene of interest may code for an antisense RNA, a ribozyme, or a polypeptide of interest.
  • the expression cassette of the invention makes it possible to express, overexpress, or inhibit the expression of a gene of interest.
  • This modulation of the expression of the gene of interest may preferably be controlled by the application or non-application of a diet deficient in one or more amino acids, preferably (an) essential amino acid(s).
  • chemokines and cytokines interferon ⁇ , ⁇ , or ⁇ , interleukin (IL), specifically IL-2, IL-6, IL-10, or IL-12, tumor necrotizing factor (TNF), colony stimulating factor (GM-, CSF, C-CSF, M-CSF, etc.), MIP-1 ⁇ , MIP-1 ⁇ , RANTES, monocyte chemoattractant protein such as MCP-1, etc.), cell receptors (in particular, those recognized by the HIV virus), receptor ligands, coagulation factors (Factor VIII, Factor IX, Factor X, thrombin, C protein, etc.), growth factors (FGF [Fibroblast Growth Factor], VEGF [Vascular Endothelial Growth Factor]), enzymes (kinases, phosphatases, urease, renin, metalloproteinase, NOS [nitric oxide synthetase], S
  • a functional copy of the defective gene will be used, e.g., a gene coding for Factor VIII or IX in hemophilia A or B, dystrophin (or mini-dystrophin) in Duchenne and Becker muscular dystrophies, insulin in diabetes, and the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) protein in cystic fibrosis.
  • a gene coding for Factor VIII or IX in hemophilia A or B dystrophin (or mini-dystrophin) in Duchenne and Becker muscular dystrophies
  • insulin in diabetes and the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) protein in cystic fibrosis.
  • CFTR Cystic Fibrosis Transmembrane Conductance Regulator
  • RNA for inhibiting the start or progression of tumors or cancers, we preferably use a gene of interest coding for an antisense RNA or an interfering RNA (miRNA, siRNA, dsRNA, shRNA, etc.), a ribozyme, a cytotoxic product (such as the thymidine kinase of Herpes Simplex Virus 1 [TK-HSV-1], ricin, cholera and diphtheria toxins, a product of the FCY1 and FUR1 yeast genes coding for uracyl phosphoribosyl transferase or cytosine desaminase), an immunoglobulin, a cell division or signal transduction inhibitor, an expression product of a tumor suppressor gene (p53, Rb, p′73, DCC, etc.), an immune-system-simulating polypeptide, a tumor-associated antigen (MUC-1, BRCA-1, early or late antigens [E6, E7, L1, L2, etc.
  • a gene of interest that inhibits the expression of a protein would be an shRNA directed against the beta2ACh receptor, which could be used to alleviate tobacco addiction (Maskos et al., Nature 2005).
  • an immunoprotective polypeptide an antigenic epitope, an antibody, the extracellular domain of the CD4 receptor (sCD4; Traunecker et al., 1988, Nature 331, 84-86), an immunoadhesin (e.g., a CD4-IgG immunoglobulin hybrid, Capon et al., 1989, Nature 33 7, 525-531; Byrn et al., 1990, Nature 344, 667-670), an immunotoxin (e.g., fusion of the 2F5 antibody or of the CD4-2F4 immunoadhesin to angiogenin; Kurachi et al., 1985, Biochemistry 24, 5494-5499), a trans dominant variation (EP 0614980, W095/16780), a cytotoxic product such as one of those mentioned above, or an IFN ⁇ or - ⁇ .
  • an immunoprotective polypeptide e.g., an antigenic epitope, an antibody, the extracellular domain of the CD4 receptor
  • One of the genes of interest may also be a selection gene enabling the selection or identification of the transfected or transduced cells.
  • neo coding for neomycin phosphotransferase
  • dhfr Dihydrofolate Reductase
  • CAT Chloramphenicol Acetyl Transferase
  • pac Puromycin Acetyl Transferase
  • gpt Xanthine Guanine Phosphoribosyl Transferase
  • the expression cassette of the invention may include additional elements that improve its expression or maintenance in the host cell (replication origins, integration elements in the cell genome, intronic sequences, poly A transcription termination sequences, tripartite leaders, etc.). These elements are known in the art.
  • the gene of interest may also comprise, upstream of the coding region, a sequence coding for a signal peptide enabling its secretion from the host cell.
  • the signal peptide may be that of the gene in question or heterologous (originating from any secreted or synthetic gene).
  • the gene of interest contains a terminator.
  • the expression cassette of the invention also includes the 5′UTR sequence of the ATF4 gene (SEQ ID NO: 8, Vattem et al., PNAS, 2004; Lu et al., J. Cell. Biol. 2004) or a similar sequence, upstream of the cassette's translational start site.
  • a similar sequence means a 5′UTR sequence of a gene having the same translational regulation as ATF4.
  • genes having a similar 5′ UTR sequence include, but are not limited to: GADD34 (Lee et al., J Biol Chem, 2009), ATFS (Zhou et al., J Biol Chem, 2008), and BACE1 (Zhou et al, Mol Cell Biol, 2006).
  • Another goal of the invention is a vector including an expression cassette according to the invention.
  • this may be a synthetic vector (cationic lipids, polymer liposomes, etc.), a plasmid, or a viral vector.
  • Felgner et al. 1987, Proc. West. Pharmacol. Soc. 32, 115-121; Hodgson and Solaiman, 1996, Nature Biotechnology 14, 339-342; Remy et al., 1994, Bioconjugate Chemistry 5, 647-654.
  • they may be polymers, cationic lipids, liposomes, nuclear proteins, or neutral lipids. These substances may be used alone or in combination.
  • One possible combination is a recombinant plasmid vector combined with cationic lipids (DOGS, DC-CHOL, spermine-chol, spermidine-chol, etc.) and neutral lipids (DOPE).
  • Plasmids can be used in the context of the present invention. They may be cloning and/or expression vectors. In general, they are known in the art, and a number of them are commercially available, but it is also possible to construct or modify them using genetic manipulation techniques. By way of examples, we may mention the plasmids derived from pBR322 (Gibco BRL), pUC (Gibco BRL), pBluescript (Strata faux), pREP4, pCEP4 (Invitrogene), or p Poly (Lathe et al., 1987, Gene 57, 193-201).
  • a plasmid implemented in the present invention contains a replication origin that ensures the start of replication in a producer cell and/or a host cell (for example, the CoIEI origin will be used for a plasmid to be produced in E. coli, and the oriP/EBNAI system will be used if it is to be self-replicative in a mammal host cell, Lupton and Levine, 1985, Mol. Cell. Biol. 5, 2533-2542; Yates et al., Nature 313, 812-815). It may also include a selection gene for selecting or identifying the transfected cells (complementation of an auxotrophic mutation, gene coding for resistance to an antibiotic, etc.). It may also include additional elements that improve its maintenance and/or its stability in a given cell (a cer sequence that encourages monomer maintenance of a plasmid, integration sequences in the cell genome).
  • a viral vector When a viral vector is involved, it may be a vector derived from an adenovirus, a lentivirus, a retrovirus, an adenovirus-associated virus (AAV), a herpes virus, an alphavirus, a parvovirus, a poxvirus (fowlpox, canarypox, vaccinia viruses, in particular of the MVA (Modified Virus Ankara) or Copenhagen strains, etc.) or a foamy virus.
  • AAV adenovirus-associated virus
  • AAV adenovirus-associated virus
  • herpes virus an alphavirus
  • a parvovirus a poxvirus (fowlpox, canarypox, vaccinia viruses, in particular of the MVA (Modified Virus Ankara) or Copenhagen strains, etc.) or a foamy virus.
  • a nonreplicative and, optionally, nonintegrative vector will be used.
  • Retroviruses have the property of in
  • a suitable retroviral vector for the implementation of the present invention comprises LTR (Long Terminal Repeat) terminal sequences and an encapsidation region. It may derive from a retrovirus of any origin (murine, primate, feline, human, etc.) and, in particular, may derive from a retrovirus selected from the group including MoMuLV (Moloney Murine Leukemia Virus), MVS (Murine Sarcoma Virus), or Friend Murine Retrovirus (Fb29). It is propagated in an encapsidation line that is able to provide in trans the gag, pol, and/or env viral polypeptides needed for the constitution of a viral particle.
  • LTR Long Terminal Repeat
  • the retroviral vector of the invention may comprise modifications, in particular at the LTRs (replacement of the promoter region by a eukaryote promoter) or at the encapsidation region (replacement by a heterologous encapsidation region, e.g., of the VL30 type) (see French patent applications 94 08300 and 97 05203).
  • the vector is a lentiviral vector, an adenoviral vector, or a vector derived from an adenovirus-associated virus (AAV).
  • AAV adenovirus-associated virus
  • the viral vector used according to the invention may be in the form of a DNA vector or of an infectious viral particle.
  • the present invention also relates to a host cell including a vector or a cassette according to the invention.
  • a cell of this type is composed of any cell that is transfectable by a vector as described above.
  • a mammal cell preferably a human cell
  • It may be a primary or tumor cell of any origin, in particular hematopoietic (totipotent stem cell, leukocyte, lymphocyte, monocyte or macrophage, etc.), muscular (satellite cell, myocyte, myoblast, smooth muscle, etc.), cardiac, pulmonary, tracheal, hepatic, epithelial, or fibroblast, but also stem cells.
  • hematopoietic totipotent stem cell, leukocyte, lymphocyte, monocyte or macrophage, etc.
  • muscular satellite cell, myocyte, myoblast, smooth muscle, etc.
  • cardiac pulmonary, tracheal, hepatic, epithelial, or fibroblast, but also stem cells.
  • Another goal of the present invention is a pharmaceutical composition including an expression cassette of the invention, an expression vector of the invention, or a host cell of the invention.
  • this type of pharmaceutical composition is intended for use in the treatment and/or prevention of diseases using gene therapy.
  • a composition of the invention is more specifically intended for use in the preventive or curative treatment of diseases using gene therapy (including immunotherapy) and applies more specifically to proliferative diseases (cancers, tumors, dysplasias, etc.), infectious—specifically, viral—diseases (induced, e.g., by the Hepatitis B or C viruses, HIV [Human Immunodeficiency Virus], herpes, retroviruses, etc.), genetic diseases (cystic fibrosis, myopathies, hemophilias, diabetes, etc.), cardiovascular diseases (restenosis, ischemia, dyslipidemia, etc.), or neurological diseases (psychiatric diseases, neurodegenerative diseases such as Parkinson's or Alzheimer's, addictions [e.g., to tobacco, alcohol, or drugs], epilepsy, etc.).
  • proliferative diseases cancers, tumors, dysplasias, etc.
  • infectious—specifically, viral—diseases induced, e.g., by the Hepati
  • a composition according to the invention may be manufactured following conventional practices for local, parenteral, or digestive administration, but also by stereotaxy. Specifically, a therapeutically effective quantity of the therapeutic or prophylactic agent is combined with a pharmaceutically acceptable support.
  • a pharmaceutically acceptable support There are multiple routes of administration. We may mention, e.g., the intragastric, subcutaneous, intracardiac, intramuscular, intravenous, intraarterial, intraperitoneal, intratumoral, intranasal, intrapulmonary, or intratracheal routes. For these final three embodiments, spray administration or instillation is advantageous.
  • Administration can take place in a single dose or in a dose that is repeated one or more times after a certain time interval has elapsed.
  • the administration route and appropriate doses vary based on various parameters, e.g., involving the individual, the pathology, the gene of interest to be transferred, or the administration route.
  • doses including from 0.01 to 100 mg DNA, preferably 0.05 to 10 mg and, especially preferred, from 0.5 to 5 mg may be implemented.
  • the formulation may also include a pharmaceutically acceptable diluent, adjuvant, or excipient, as well as solubilizers, stabilizers, and preservatives.
  • a preferred composition is in injectable form. It may be formulated in an aqueous, saline (phosphate, monosodium, disodium, magnesium, potassium, etc.), or isotonic solution.
  • the present invention also relates to the therapeutic or prophylactic use of an expression cassette, a vector, or a host cell of the invention, for the preparation of a drug for the transfer and expression of a gene of interest (included in said expression cassette, said vector, or said host cell) in a cell or a host organism.
  • the expression cassette, vector, or host cell of the invention is intended for treating the human or animal body using gene therapy.
  • the goal of the invention is therefore an expression cassette, a vector, or a host cell of the invention for use in treating diseases using gene therapy.
  • the drug may be administered directly in vivo (e.g., by intravenous injection, into an accessible tumor, into the lungs using a spray, into the vascular system using an appropriate probe, or by stereotaxy into the brain).
  • the ex vivo approach may also be used, which consists of sampling cells from the patient (bone marrow stem cells, peripheral blood lymphocytes, muscle cells, etc.), transfecting them in vitro using techniques known in the art, and re-administering them to the patient after an optional amplification step.
  • a preferred use consists of treating or preventing cancers, tumors, and diseases resulting from undesired cell proliferation.
  • cancers of the breast, uterus in particular, those induced by HPV papillomaviruses
  • prostate in particular, those induced by HPV papillomaviruses
  • lung bladder
  • liver colon
  • pancreas stomach
  • esophagus larynx
  • central nervous system central nervous system
  • blood lymphomas, leukemia, etc.
  • cardiovascular diseases e.g., for inhibiting or delaying the proliferation of smooth muscle cells of the vascular wall (restenosis).
  • infectious diseases it may be used in treating AIDS (Acquired Immune Deficiency Syndrome).
  • it is particularly appropriate for the treatment of neurological diseases (psychiatric, neurodegenerative diseases, addictions, etc.).
  • the invention also extends to a method for treating diseases using gene therapy, wherein said method includes:
  • the term “patient” refers to a mammal, preferably a human, suffering from a pathology that can be treated by gene therapy.
  • pathologies are known in the art, and include cancers, infectious diseases, cardiovascular diseases, and genetic diseases. Examples are provided in the present description.
  • the administration step is performed using methods known in the art.
  • the induction step is performed by causing said patient to experience an environmental stimulus that induces the phosphorylation of eIF2 ⁇ (and hence the activation of the eIF2 ⁇ /ATF4 signaling pathway).
  • the stimulus experienced by the patient is an amino acid deficiency, preferably an essential amino acid deficiency.
  • the expression cassette (included or not included in a vector or host cell) of the invention more specifically includes the CARE regulatory sequence of a gene selected from the group including TRIB3, CHOP, ASNS, ATF3, and SNAT2, or a sequence derived therefrom.
  • the promoter used is the promoter defined by the SEQ ID NO: 7 sequence.
  • the stimulus experienced by the patient is the induction of a viral infection or the administration of a molecule mimicking a viral infection.
  • the eIF2 ⁇ /ATF4 pathway is activated during a viral infection by the presence of double-stranded RNA produced by the virus, by the cytokines and interferon, or by PACT protein and heparin. Hence, a viral infection may be mimicked by one of these elements.
  • the stimulus experienced by the patient is the induction of endoplasmic reticulum stress.
  • This type of stress may be induced by a number of drugs, such as the anticancer drug bortezomyb, tunicamycin, dithiothreitol, thapsigargin, or brefeldin A, or by a lipopolysaccharide injection.
  • the stimulus experienced by the patient is the induction of a heme deficiency.
  • the stimulus experienced by the patient is a lipid-heavy diet.
  • the stimulus experienced by the patient is heat shock or osmotic shock.
  • the patient is placed on a diet deficient in an essential amino acid (also referred to as an indispensable amino acid).
  • the essential amino acids are phenylalanine, leucine, methionine, lysine, isoleucine, valine, threonine, tryptophan, and histidine.
  • an “amino-acid-deficient diet” is defined as any means or any composition for enforcing an amino acid deficiency in a patient as described above.
  • the patient is caused to have a deficiency in an essential amino acid.
  • This may involve compositions including a cocktail of free amino acids in which an amino acid, preferably an essential amino acid, is absent.
  • This type of diet will be preferably administered after a short-term fast, and may be given in the form of a cocktail of free amino acids or a full meal in which the proteins are replaced by a mixture of free amino acids.
  • the essential amino acid blood depletion occurs very quickly (a few minutes after consuming the deficient meal) and may be stopped very quickly by administering the lacking essential amino acid.
  • the deficiency of any of the nine indispensable amino acids is functional.
  • the selection of the amino acid (or amino acids) to be withdrawn from the patient's food may be made by a person skilled in the art, in order to minimize treatment-related side effects, and taking into account the ease with which deficient food may be prepared.
  • the patient is placed on successive diets that are deficient in one amino acid, with each being deficient in a different amino acid (e.g., a leucine-deficient diet, followed by a valine-deficient diet, then a lysine-deficient diet, etc.).
  • a different amino acid e.g., a leucine-deficient diet, followed by a valine-deficient diet, then a lysine-deficient diet, etc.
  • a cassette of the invention for inducing the expression of the gene via an amino acid deficiency makes it possible to precisely control the start and duration of the induction period for the expression of the gene of interest. Moreover, the post-induction response, as well as the extinction of the expression of the gene of interest (by administering the lacking amino acid), are rapid. Additionally, the expression cassette of the invention leads to a low basal expression level and a high activation level.
  • the patient is administered an amino-acid-consuming enzyme.
  • amino-acid-consuming enzyme is asparaginase.
  • Said amino-acid-consuming enzyme is preferably administered intravenously. This type of administration is well known to a person skilled in the art (Pieters R. et al., Cancer, 2011; Patil S. et al., Cancer Treat Rev, 2011).
  • the cassette of the invention is used in pathologies wherein the eIF2alpha/ATF4 pathway is activated, such as cancers (Ye et al., EMBO J, 2010) or epilepsy (Carnevalli et al., Biochem J, 2006).
  • the step for inducing the expression of the gene of interest (ii) of the method of the invention is no longer necessary.
  • the invention relates to a method for treating pathologies wherein the eIF2alpha/ATF4 pathway is activated using gene therapy, with said method including a step for administering an expression cassette, a vector, a host cell, or a pharmaceutical composition of the invention to a patient.
  • Such pathologies include, in particular, cancers and epilepsy.
  • the invention relates to a method for treating diseases using gene therapy, with said method including:
  • the patient may be placed on successive amino-acid-deficient diets, with each being deficient in a different amino acid as described above. It is also possible to place the patient on a diet that is deficient in one or more amino acids, preferably a diet that is deficient in one or more essential amino acids.
  • the 2XAARE TRIB3-TK-LUC construction shown in FIG. 2 was obtained by subcloning a double-stranded oligonucleotide containing two copies of the CARE/AARE sequence of TRIB3 ( ⁇ 7131 to ⁇ 7033) at the MluI-Xhol site of the TATA-TK-LUC plasmid construction containing the coding sequence of the luciferase gene originating from pGL3 basic (Promega). The construction was sequenced, and then the leucine deficiency response was tested in transient transfection in HepG2 human cells (liver hepatoma) and in murine cells (MEF: Mouse Embryonic Fibroblasts).
  • the DNA fragment corresponding to the sequences of the 2XARRE-TK-LUC transgene was then cloned at the BamHi/XbaI sites of the pRRL.PPT.SF.GFPpre 1xHS4 lentiviral vector (Schambach A, Maetzig T, Loew R, Baum C. Mol. Ther. 2007 June; 15(6): 1167-73) containing the chicken ⁇ -globin 5′HS4 “insulator” sequences.
  • HeLa cells were infected by these lentiviral particles.
  • the lentiviral particles were microinjected into the perivitelline space of an oocyte at the one-cell stage originating from C5BL/6JxDB/2J mice (Charles River, Wilmington, Mass.). This lentiviral germ line integration yielded over 50% of founders carrying the transgene. Fifteen independent lines were thereby obtained, but only five founders had at least one copy of the integrated transgene. F1 offspring were obtained for these five selected F0 founder mice.
  • Luciferase activity in the cell or tissue extracts was measured by using a commercial kit (YELEN, Ensue La Redonne, France).
  • the relative luciferase activity corresponds to the ratio between luciferase activity and protein quantity.
  • Luciferase activity was visualized on the living AARE-LUC mice with a NightOWL II LB 983 NC100 in vivo imaging unit (Berthold Technologies, Bad Wildbad, Germany).
  • This system uses a slow-scan ultrasensitive CCD camera cooled using the Peltier effect, equipped with a 25 mm/0.95 lens located in a sealed, heat-controlled darkroom, enabling the detection of very low levels of light emitted by a cell expressing a tracer gene such as luciferase. It is also equipped with an integrated gas anesthesia system.
  • mice were anesthetized with isoflurane (induction 5% isoflurane, maintenance at 2% in 70% air—30% oxygen) and received an intraperitoneal injection of an aqueous luciferin solution (Caliper LIFE SCIENCES, 150 mg/kg), 10 minutes prior to measuring photon emission (2 ⁇ 4 min. of integration, 8 ⁇ 8 pixel binning), in order to obtain a uniform biodistribution of the substrate.
  • the bioluminescence images are presented as pseudo-color images superimposed onto a photo acquired prior to the bioluminescence image in grayscale, using the WinLight software program (Berthold Technologies). The intensity of the bioluminescent signal is then quantified at the regions of interest using the WinLight software program and expressed in number of photons per second.
  • the evaluation of the inducibility of the AARE-TK-LUC transgene to leucine deficiency was performed by measuring luciferase activity in the various tissues from the various transgenic lines. Mice of approximately two months of age were habituated, over seven days, to a control (CTL) diet containing all of the indispensable amino acids. Next, after being fasted for 16 hours, they were fed either the CTL diet or a leucine-deficient ( ⁇ Leu) diet, and then killed so that samples of various tissues could be taken.
  • CTL control
  • ⁇ Leu leucine-deficient
  • the luciferase activity analysis shows that consuming a leucine-free diet causes a strong induction of LUC activity in the liver, intestine, pancreas, and brain ( FIG. 3 ). This expression profile of the LUC gene was confirmed by measuring the level of LUC mRNA.
  • mice were first acclimatized with a CTL diet for seven days, and then two types of experiments were conducted:

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US14/357,160 2011-11-08 2012-11-06 Inducible expression cassette, and uses thereof Abandoned US20140322184A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1103392A FR2982277B1 (fr) 2011-11-08 2011-11-08 Cassette d'expression inductible et ses utilisations
FR1103392 2011-11-08
PCT/EP2012/004610 WO2013068096A1 (fr) 2011-11-08 2012-11-06 Cassette d'expression inductible et ses utilisations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/004610 A-371-Of-International WO2013068096A1 (fr) 2011-11-08 2012-11-06 Cassette d'expression inductible et ses utilisations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/235,559 Division US20190224337A1 (en) 2011-11-08 2018-12-28 Inducible expression cassette, and uses thereof

Publications (1)

Publication Number Publication Date
US20140322184A1 true US20140322184A1 (en) 2014-10-30

Family

ID=47146334

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/357,160 Abandoned US20140322184A1 (en) 2011-11-08 2012-11-06 Inducible expression cassette, and uses thereof
US16/235,559 Abandoned US20190224337A1 (en) 2011-11-08 2018-12-28 Inducible expression cassette, and uses thereof
US17/449,374 Pending US20220040329A1 (en) 2011-11-08 2021-09-29 Inducible expression cassette, and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/235,559 Abandoned US20190224337A1 (en) 2011-11-08 2018-12-28 Inducible expression cassette, and uses thereof
US17/449,374 Pending US20220040329A1 (en) 2011-11-08 2021-09-29 Inducible expression cassette, and uses thereof

Country Status (5)

Country Link
US (3) US20140322184A1 (fr)
EP (1) EP2776568B1 (fr)
ES (1) ES2651672T3 (fr)
FR (1) FR2982277B1 (fr)
WO (1) WO2013068096A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256799A1 (en) * 2013-02-28 2014-09-11 City Of Hope REPLICATION CAPABLE rAAV VECTORS ENCODING INHIBITORY siRNA AND METHODS OF THEIR USE
WO2017207744A1 (fr) * 2016-06-03 2017-12-07 Institut National De La Recherche Agronomique (Inra) Expression régulée par un régime d'un acide nucléique codant pour une protéine pro-apoptotique
KR20190031230A (ko) * 2016-06-03 2019-03-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cas9 뉴클레아제를 암호화하는 핵산의 식이 제어된 발현 및 이의 용도

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024008776A1 (fr) 2022-07-05 2024-01-11 Nutritheragene Expression contrôlée d'un transgène dans des cellules t ou nk humaines à utiliser en immunothérapie cellulaire
WO2024100176A1 (fr) 2022-11-10 2024-05-16 Nutritheragene Thérapie génique contrôlée de maladies oculaires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700169B1 (fr) 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
FR2713651B1 (fr) 1993-12-13 1996-04-19 Transgene Sa Nouvelle composition pour un effet antiviral.
WO2001048182A2 (fr) * 1999-12-28 2001-07-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Système d"expression inductible par acide aminé
EP1586902A3 (fr) * 2004-03-30 2006-02-15 F.Hoffmann-La Roche Ag ANGPTL4/FIAF comme marqueur pour la modulation de PPARdelta
JP2008541764A (ja) * 2005-06-01 2008-11-27 バイオテック・インスティチュート・フォー・インターナショナル・イノベーション・インコーポレーテッド グルコース誘導性のインシュリンの発現及び糖尿病を治療する方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Bruhat (MOLECULAR AND CELLULAR BIOLOGY, October 1, 2000, Vol. 20, no. 19, pg 7192-7204) *
Deonarain (1998, Expert Opin. Ther. Pat., Vol. 8, pages 53-69) *
Edelstein (Journal Gene Med., 2004, Vol. 6, pg 597-602) *
Johnson-Saliba (Curr. Drug. Targets, 2001, Vol. 2, pg 371-399) *
Luo (Nature Biotechnol., 2000, Vol. 18, pg 33-37) *
Palu (J. Biotechnol., 1999, Vol. 68, pg 1-13) *
Pfeifer (Annu. Rev. Genomics. Hum. Genet. 2001, Vol. 2, pg 177-211) *
Shoji (Current Pharmaceutical Design, 2004, Vol. 10, pg 785-796) *
Verma (Sept. 1997, Nature, Vol. 389, pages 239-242) *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370662B2 (en) 2013-02-28 2019-08-06 City Of Hope Replication capable rAAV vectors encoding inhibitory siRNA and methods of their use
US9783805B2 (en) * 2013-02-28 2017-10-10 City Of Hope Replication capable rAAV vectors encoding inhibitory siRNA and methods of their use
US20140256799A1 (en) * 2013-02-28 2014-09-11 City Of Hope REPLICATION CAPABLE rAAV VECTORS ENCODING INHIBITORY siRNA AND METHODS OF THEIR USE
CN111110867A (zh) * 2016-06-03 2020-05-08 国家农艺研究院 编码促凋亡蛋白的核酸的膳食受控表达
CN109689873A (zh) * 2016-06-03 2019-04-26 国家农艺研究院 编码促凋亡蛋白的核酸的膳食受控表达
CN109906271A (zh) * 2016-06-03 2019-06-18 国家医疗保健研究所 编码Cas9核酸酶的核酸的饮食控制的表达及其用途
JP2019517262A (ja) * 2016-06-03 2019-06-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｃａｓ９ヌクレアーゼをコードする核酸の食餌コントロール発現及びその使用
KR20190031230A (ko) * 2016-06-03 2019-03-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cas9 뉴클레아제를 암호화하는 핵산의 식이 제어된 발현 및 이의 용도
WO2017207744A1 (fr) * 2016-06-03 2017-12-07 Institut National De La Recherche Agronomique (Inra) Expression régulée par un régime d'un acide nucléique codant pour une protéine pro-apoptotique
JP2020072699A (ja) * 2016-06-03 2020-05-14 アンスティテュート ナショナル ド ラ ルシェルシュ アグロノミク（アイエヌアールエー） アポトーシス促進タンパク質をコードする核酸の食事制御された発現
EP3666908A1 (fr) * 2016-06-03 2020-06-17 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Expression régulée par un régime d'un acide nucléique codant pour une protéine pro-apoptotique
KR102317622B1 (ko) * 2016-06-03 2021-10-26 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) Cas9 뉴클레아제를 암호화하는 핵산의 식이 제어된 발현 및 이의 용도
JP2022008425A (ja) * 2016-06-03 2022-01-13 アンスティテュート ナショナル ド ルシェルシュ プール ラグリキュルテュール，ラリマンタシォン エ ランヴィロンヌマン アポトーシス促進タンパク質をコードする核酸の食事制御された発現
RU2771383C2 (ru) * 2016-06-03 2022-05-04 Энсэрм (Энститю Насьональ Де Ла Санте Э Де Ла Решерш Медикаль) Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения
JP7396566B2 (ja) 2016-06-03 2023-12-12 アンスティテュート ナショナル ド ルシェルシュ プール ラグリキュルテュール，ラリマンタシォン エ ランヴィロンヌマン アポトーシス促進タンパク質をコードする核酸の食事制御された発現
JP7436145B2 (ja) 2016-06-03 2024-02-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｃａｓ９ヌクレアーゼをコードする核酸の食餌コントロール発現及びその使用

Also Published As

Publication number Publication date
ES2651672T3 (es) 2018-01-29
FR2982277A1 (fr) 2013-05-10
EP2776568B1 (fr) 2017-10-18
US20220040329A1 (en) 2022-02-10
FR2982277B1 (fr) 2015-08-21
EP2776568A1 (fr) 2014-09-17
WO2013068096A1 (fr) 2013-05-16
US20190224337A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
US20220040329A1 (en) Inducible expression cassette, and uses thereof
JP2021530985A (ja) フソソームの組成物及びその使用
US8569065B2 (en) Compositions and methods for the delivery of biologically active RNAs
JP2022507454A (ja) Ｃｎｓ送達のためのフソソーム組成物
US20230048166A1 (en) Fusosome compositions for hematopoietic stem cell delivery
CN108603196A (zh) Rna向导的对人类jc病毒和其他多瘤病毒的根除
PT1792997E (pt) Adn triplex lentiviral, vetores e células recombiantes contendo adn triplex lentiviral
US20130164845A1 (en) Compositions and Methods for the Delivery of Biologically Active RNAs
JP2002518997A (ja) レトロウイルス送達システム
JP2023521663A (ja) 標的化脂質粒子及び組成物ならびにその使用
CN114765990A (zh) 双重病毒和双重溶瘤病毒以及治疗方法
JP2002508338A (ja) レンチウィルスベクターの治療使用
US20230391836A1 (en) Amino acid sequence that can destroy cells, and related nucleotide sequence and related uses thereof
US20240052328A1 (en) Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
EP1264892A2 (fr) Vecteurs lentivirauxs comprenant des promoteurs spécifiques des cellules endotheliales
JP4766297B2 (ja) 非ウィルス由来のエンハンサーと、ｃＰＰＴと、ＣＴＳとを含むことを特徴とするベクター
WO2024020320A2 (fr) Vecteurs d'adn non immunogènes circulaires non viraux
US20160002643A1 (en) Compositions And Methods To Enhance Protein Expression
WO2024107983A1 (fr) Particules de type virus à tropisme programmable et leurs procédés d'utilisation aux fins d'une administration à des cellules
CA2433867A1 (fr) Vecteurs et systemes d'encapsulation destines a la transduction dans des cellules quiescentes
AU2002246958A1 (en) Vectors and packaging systems for transduction into quiescent cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FAFOURNOUX, PIERRE;JOUSSE, CELINE;REEL/FRAME:037281/0409

Effective date: 20150705

Owner name: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRUHAT, ALAIN;MAURIN, ANNE-CATHERINE;AVEROUS, JULIEN;REEL/FRAME:037281/0442

Effective date: 20150705

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION